Proqr Therapeutics N.V. current report, Q1 FY2015

ProQR Therapeutics N.V. Form 6-K Summary

Business Context and Reporting Period

This Form 6-K, filed on February 26, 2015, by ProQR Therapeutics N.V., a foreign private issuer based in Leiden, The Netherlands, serves to furnish unaudited financial statements and a press release. The reporting period covers the three months and the full year ended December 31, 2014.

Key Financial Metrics

The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are contained within the attached exhibits (Exhibit 99.1: Unaudited financial statements; Exhibit 99.2: Press Release) but are not present in the cover document text.

Material Changes

The filing text does not provide specific details regarding material changes versus prior periods. It only indicates that results for the three months and year ended December 31, 2014, are announced in the attached press release.

Guidance, Outlook, and Risks

The cover document does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. Such information is expected to be found in the furnished press release (Exhibit 99.2).

Investor Verification Checklist

  • Review Exhibit 99.1 for specific revenue, net loss, and cash burn rates for the three months and year ended December 31, 2014.
  • Examine Exhibit 99.2 for management's discussion of clinical progress, pipeline updates, and liquidity outlook.
  • Verify the company's cash position and runway based on the unaudited financial statements.
  • Check for any new material agreements or regulatory developments mentioned in the press release.